HYTN Successfully Releases Cannabis Products in Germany and Accepts Reorder
Source: HYTN Innovations Inc.
March 27, 2026 18:46 ET
HYTN Successfully Releases
Cannabis Products in
Germany and Accepts
Reorder
VANCOUVER, British Columbia, March 27, 2026 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE:
HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a pharmaceutical manufacturer
specializing in products containing psychoactive and psychotropic compounds, including cannabis,
is pleased to announce that wholesale cannabis products previously exported to Germany during
the prior quarter have now been successfully released for sale in the German market.
The release follows completion of required import, quality control, and market release procedures
for Germany’s regulated medical cannabis market. Following this milestone, the Company has
accepted a reorder for additional wholesale product.
This milestone builds on HYTN’s previously announced strategic supply framework for Germany and
further demonstrates the Company’s ability to execute within highly regulated international
medical cannabis markets.
“The successful release of product into the German market is a signicant commercial milestone,”
said Elliot McKerr, Chief Executive Ofcer of HYTN. “It validates that our GMP platform meets the
stringent requirements of one of the world’s most tightly regulated medical cannabis markets. The
acceptance of a reorder is a positive indicator as we continue toward building recurring
international revenue channels.”
HYTN believes the successful German market release of this shipment further validates the
commercial progress reected in its recent nancial results and supports the Company’s strategy of
expanding pharmaceutical-grade cannabis sales into highly regulated international markets
About HYTN Innovations Inc.
HYTN Innovations Inc. is a pharmaceutical company specializing in the formulation, manufacturing,
marketing, and sale of products containing psychoactive and psychotropic compounds, including
cannabis-derived cannabinoids. The Company focuses on serving federally regulated markets by
applying pharmaceutical-grade development, manufacturing, and quality systems. HYTN advances
products to market by identifying regulated market opportunities and leveraging its integrated
development and commercialization platform.
For more information contact:
Elliot McKerr
Chief Executive Ofcer
HYTN Innovations Inc.
HYTN Investor Relations:
1.866.590.9289
The Canadian Securities Exchange (CSE) has not reviewed, approved, or disapproved the contents
of this press release.
Forward-Looking Statements
Certain statements contained in this press release constitute forward-looking information within
the meaning of applicable securities laws. Forward-looking information relates to future events or
future performance and is generally identiable by the use of words such as “expect,” “intend,”
“may,” “will,” “anticipate,” “believe,” and similar expressions, or by statements regarding matters
that are not historical facts. Such statements are based on the Company’s current beliefs,
assumptions, and expectations regarding future events and operating conditions.
This press release contains forward-looking information relating to, among other things: the
successful release and sale of cannabis products in the German market; the acceptance and
fulllment of the reorder; the continuation and growth of commercial activity in Germany; and the
Company’s ability to execute within highly regulated international medical cannabis markets.
Forward-looking information is based on certain assumptions, including, but not limited to: the
assumption that all required regulatory approvals and processes will be maintained or obtained as
expected; that product quality and supply will meet German market requirements; that customer
demand will continue; and that the Company will have sufcient resources to fulll orders. These
assumptions are based on information currently available to the Company. Although management
believes such assumptions to be reasonable, there can be no assurance that they will prove to be
correct.
Forward-looking information is subject to known and unknown risks, uncertainties, and other
factors that may cause actual results, events, or outcomes to differ materially from those expressed
or implied by such forward-looking information. These risks and uncertainties include, without
limitation: regulatory risks in Canada and Germany; delays or failures in import, quality control, or
market release processes; changes in customer demand or reorder volumes; operational risks;
supply chain disruptions; and nancing and liquidity risks.
The forward-looking information contained in this press release is made as of the date hereof, and
the Company does not undertake any obligation to update or revise any forward-looking
information, whether as a result of new information, future events, or otherwise, except as required
by applicable securities laws. Readers are cautioned not to place undue reliance on forward-looking
information.
